Efficacy and safety of intravenous imatinib in COVID-19 ARDS: a randomized, double-blind, placebo-controlled clinical trial

Table 4 Trial efficacy endpoints: P_aO₂/FiO₂ ratio and exploratory outcomes

Population	Outcome	Change per day exposed to treatment	95% CI
ITT	PaO₂/FiO₂*	− 0.09	− 4.11 to 4.01
ITT	EVLWi	− 0.14	− 0.41 to 0.13
PP	EVLWi	− 0.68	− 1.39 to 0.017
ITT	Oxygenation index	+ 0.32	− 0.21 to 0.83
ITT	Driving pressure	+ 0.31	− 0.21 to 0.83
ITT	Compliance	− 1.54	− 4.66 to 1.54
ITT	Mechanical power	+ 0.54	− 0.40 to 1.46
ITT	PVPi	− 0.05	− 0.12 to 0.01
ITT	SOFA score	− 0.08	− 0.32 to 0.16

Table summarizing the secondary outcomes assessed by linear mixed effect modelling, with the placebo group as the reference group
CI confidence interval; EVLWi extravascular lung water index in ml/kg; ITT intention-to-treat; PaO₂/FiO₂ partial pressure of oxygen to fraction of inspired oxygen (FiO₂) ratio; PP per-protocol; PVPi pulmonary vascular permeability index; SOFA sequential organ failure assessment
^*Prioritized secondary outcome

ISSN: 1364-8535